Compare Micron Technology, Inc. (MU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs GeneDx Holdings Corp — how do they compare? Micron Technology, Inc. trades at $1,023.7 (market cap $1.13T), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Micron Technology, Inc. is far larger — about 441.4× GeneDx Holdings Corp's market cap, and Micron Technology, Inc. pays a 0.05% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MU | WGS | |
|---|---|---|
Market Cap | $1.13T | $2.56B |
Sector | Technology | Technology |
52-Week High | $1.21K | $167.51 |
52-Week Low | $140.00 | $34.51 |
Enterprise Value | $1.11T | $2.60B |
Dividend Yield | 0.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,000.26, down 1.61% on the day, but remains in a bullish technical trend with strong analyst support. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $25.11 surpassing the $20.98 forecast. Fundamentals show robust growth, with 2025 revenue at $37.38 billion and net income margin of 55.91%. Positive sentiment is driven by AI-driven memory demand and projected 2026 revenue of $90.3 billion.
Outlook is bullish given memory supply constraints and AI tailwinds, but risks include cyclical industry volatility and high valuation multiples. The consensus price target is $1,540 with 82.9% of analysts rating it a buy. Investors should weigh strong cash flow growth against potential margin pressures if demand softens.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
